title: Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients.
abstract: Literature suggests that disease severity and neurotransmitter signaling pathway genes can accurately identify antipsychotic response in schizophrenia patients. However, putative role of signaling molecules has not been tested in schizophrenia patients based on severity of illness, despite its biological plausibility. In the present study we investigated the possible association of polymorphisms from five candidate genes RGS4, SLC6A3, PIP4K2A, BDNF, PI4KA with response to antipsychotic in variably ill schizophrenia patients. Thus in present study, a total 53 SNPs on the basis of previous reports and functional grounds were examined for their association with antipsychotic response in 423 schizophrenia patients segregated into low and high severity groups. Additionally, haplotype, diplotype, multivariate logistic regression and multifactor-dimensionality reduction (MDR) analyses were performed. Furthermore, observed associations were investigated in atypical monotherapy (n = 355) and risperidone (n = 260) treated subgroups. All associations were estimated as odds ratio (OR) and 95% confidence interval (CI) and test for multiple corrections was applied. Single locus analysis showed significant association of nine variants from SLC6A3, PIP4K2A and BDNF genes with incomplete antipsychotic response in schizophrenia patients with high severity. We identified significant association of six marker diplotype ATTGCT/ATTGCT (rs746203-rs10828317-rs7094131-rs2296624-rs11013052-rs1409396) of PIP4K2A gene in incomplete responders (corrected p-value = 0.001; adjusted-OR = 3.19, 95%-CI = 1.46-6.98) with high severity. These associations were further observed in atypical monotherapy and risperidone sub-groups. MDR approach identified gene-gene interaction among BDNF_rs7103411-BDNF_rs1491851-SLC6A3_rs40184 in severely ill incomplete responders (OR = 7.91, 95%-CI = 4.08-15.36). While RGS4_rs2842026-SLC6A3_rs2975226 interacted synergistically in incomplete responders with low severity (OR = 4.09, 95%-CI = 2.09-8.02). Our findings provide strong evidence that diplotype ATTGCT/ATTGCT of PIP4K2A gene conferred approximately three-times higher incomplete responsiveness towards antipsychotics in severely ill patients. These results are consistent with the known role of phosphatidyl-inositol-signaling elements in antipsychotic action and outcome. Findings have implication for future molecular genetic studies as well as personalized medicine. However more work is warranted to elucidate underlying causal biological pathway.
authors.affiliation: Genomics and Molecular Medicine, CSIR- Institute of Genomics and Integrative Biology, Delhi, India.
authors.forename: Harpreet
authors.initials: H
authors.lastname: Kaur
authors.affiliation: Genomics and Molecular Medicine, CSIR- Institute of Genomics and Integrative Biology, Delhi, India.
authors.forename: Ajay
authors.initials: A
authors.lastname: Jajodia
authors.affiliation: Genomics and Molecular Medicine, CSIR- Institute of Genomics and Integrative Biology, Delhi, India.
authors.forename: Sandeep
authors.initials: S
authors.lastname: Grover
authors.affiliation: Genomics and Molecular Medicine, CSIR- Institute of Genomics and Integrative Biology, Delhi, India.
authors.forename: Ruchi
authors.initials: R
authors.lastname: Baghel
authors.affiliation: Genomics and Molecular Medicine, CSIR- Institute of Genomics and Integrative Biology, Delhi, India.
authors.forename: Meenal
authors.initials: M
authors.lastname: Gupta
authors.affiliation: Department of Psychiatry, National Institute of Mental Health and Neuro Sciences, Bengaluru, Karnataka, India.
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Jain
authors.affiliation: Genomics and Molecular Medicine, CSIR- Institute of Genomics and Integrative Biology, Delhi, India.
authors.forename: Ritushree
authors.initials: R
authors.lastname: Kukreti
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001483:Base Sequence; D016022:Case-Control Studies; D005260:Female; D056726:Genetic Association Studies; D006801:Humans; D008297:Male; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D012559:Schizophrenia / Q000188:drug therapy / Q000235:genetics*; D012565:Schizophrenic Psychology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; C514871:PIP4K2A protein, human; D017853:Phosphotransferases (Alcohol Group Acceptor)